Kemraj Hirani

Kemraj Hirani, DPharm., has over 21 years of investigational drugs/biologics experience from bench to clinic. He serves as the principal strategic and regulatory consultant for clinical, scientific, and regulatory affairs for the University of Miami Miller School of Medicine, and biotech start-ups based on translational work of academic medical centers, including orphan products for rare diseases, including Prizm Therapeutics, Abbreos Inc, Ambulero Inc, IGEA Pharma, Betalin Therapeutics, Eyepharma Inc, as well as AAHRPP site assessor.